Homogeneous MGMT Immunoreactivity Correlates with an Unmethylated MGMT Promoter Status in Brain Metastases of Various Solid Tumors
Barbara Ingold, Peter Schraml, Frank L. Heppner et al. · 2009
Read Homogeneous MGMT Immunoreactivity Correlates with an Unmethylated MGMT Promoter Status in Brain Metastases of Various Solid Tumors by Barbara Ingold, Peter Schraml, Frank L. Heppner et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0004775.txt.
Description
Barbara Ingold and colleagues linked uniform MGMT staining to an unmethylated gene switch in brain metastases, in PLOS ONE in 2009. MGMT switch methylation predicts response of brain tumors to certain chemo drugs. Early reports on using those drugs for cancer that spread to the brain showed mixed effects across patients.
The team compared protein staining patterns with switch status in metastases from various cancers. Uniform staining matched an unmethylated, active switch. A simple stain test could thus hint at drug response. That would help select patients for therapy without complex DNA tests. Such evidence helps the field move from broad claims toward tested detail.
Catalog record
| CREATOR | Barbara Ingold, Peter Schraml, Frank L. Heppner et al. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004775